Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460224 | 0.83 | HSD17B10 (0.42) | ALDH1A1CYP3A4ALOX15HSD17B10MEN1 | |
| SCHEMBL28032461 | 0.81 | MAPT (0.42) | ALDH1A1KDM4ECYP3A4HPGDALOX15 | |
| SCHEMBL1589867 | 0.79 | AKR1C3 (0.46) | PTGS2CPN1CPB2AKR1C3AKR1C2 | |
| SCHEMBL30092945 | 0.78 | PRKCI (0.39) | ALDH1A1KDM4ECYP3A4HPGDALOX15 | |
| SCHEMBL5382824 | 0.77 | RORC (0.58) | ALDH1A1KDM4ECYP3A4HPGDALOX15 | |
| SCHEMBL30483161 | 0.75 | TSHR (0.57) | ALDH1A1KDM4EHPGDHSD17B10PTGS2 | |
| SCHEMBL6773227 | 0.75 | TSHR (0.57) | ALDH1A1KDM4EHPGDHSD17B10PTGS2 | |
| SCHEMBL4071095 | 0.75 | TSHR (0.57) | ALDH1A1KDM4EHPGDHSD17B10PTGS2 | |
| SCHEMBL17774722 | 0.75 | PRKCI (0.46) | ALDH1A1KDM4ECYP3A4HPGDALOX15 | |
| SCHEMBL17774725 | 0.75 | KDM4E (0.50) | ALDH1A1KDM4ECYP3A4HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390343-B1 | NOVEL RETINOID DERIVATIVES AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO LTD (KR) | 2009-10-14 | — | — | EP | disclosed |
| US-7166744-B2 | Retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | CHEBIGEN CO., LTD. (KR) | 2007-01-23 | — | — | US | disclosed |
| EP-1390343-A4 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO LTD (KR) | 2005-06-22 | — | — | EP | disclosed |
| EP-1390343-A1 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | Chebigen Co., Ltd. (KR) | 2004-02-25 | — | — | EP | disclosed |
| US-20030171339-A1 | Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | CHEBIGEN CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
| WO-2002096857-A1 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO., LTD. (KR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171339-A1 | Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | RXRB, RARB, RXRA | ALDH1A1 22/4885KDM4E 2832/4885CYP3A4 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.